XML 17 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2024
Jun. 20, 2024
USD ($)
shares
$ / shares
Award Timing Disclosures [Line Items]    
Award Timing MNPI Disclosure
Equity Award Grant Practices
We have had no program, plan or practice pertaining to the timing of stock option grants to NEOs coinciding with the release of material
non-public
information. Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle. Our Board or Compensation Committee may also approve grants at other times as they deem appropriate.
 
The timing of any equity grants to newly-hired employees, or in connection with promotions or other
non-routine
grants, is generally tied to the event giving rise to the award, although
non-executive
new hire stock option awards are generally approved at the beginning of the calendar month following the individual’s commencement of employment. For all stock option awards, the exercise price is no less than the closing price of our common stock on the date of the grant.
The following table sets forth information for certain stock options granted to our NEOs during 2024. In the event an issuer grants stock options or option-like instruments within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form
10-K,
Form
10-Q
or Form
8-K
containing material
non-public
information as required under Item 402(x) of Regulation
S-K,
Item 402(x) of Regulation
S-K
requires tabular disclosure of certain information related to such awards. The table below is being provided because certain of the stock options granted to our NEOs during 2024 were granted within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form
10-K,
Form
10-Q
or Form
8-K
containing material
non-public
information.
 
Name
   
Grant

Date
     
Number of

Securities

Underlying

the Award
     
Exercise
Price of

the Award

at Time of

Grant
(1)
     
Grant Date

Fair Value of

the Award
     
Percentage Change in the

Closing Market Price of the

Securities Underlying the

Award Between the Trading

Day Ending Immediately

Prior to the Disclosure of

MNPI and the Trading Day

Beginning Immediately

Following the Disclosure of

MNPI
  
Jonathan E. Lim, M.D.
      6/20/2024        632,759      $ 2.03      $ 934,458        (1.43 %) 
David M. Chacko, M.D.
      6/20/2024        278,812      $ 2.03      $ 411,750        (1.43 %) 
Shannon R. Morris, M.D., Ph.D.
      6/20/2024        137,142      $ 2.03      $ 202,531        (1.43 %) 
  
Award Timing Method We have had no program, plan or practice pertaining to the timing of stock option grants to NEOs coinciding with the release of material
non-public
information. Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle. 		 
Award Timing MNPI Considered false  
MNPI Disclosure Timed for Compensation Value false  
Jonathan E. Lim, M.D. [Member]    
Awards Close in Time to MNPI Disclosures    
Name   Jonathan E. Lim, M.D.
Underlying Securities | shares   632,759
Exercise Price | $ / shares   $ 2.03
Fair Value as of Grant Date | $   $ 934,458
Underlying Security Market Price Change   (1.43)
David M. Chacko, M.D. [Member]    
Awards Close in Time to MNPI Disclosures    
Name   David M. Chacko, M.D.
Underlying Securities | shares   278,812
Exercise Price | $ / shares   $ 2.03
Fair Value as of Grant Date | $   $ 411,750
Underlying Security Market Price Change   (1.43)
Shannon R. Morris, M.D., Ph.D. [Member]    
Awards Close in Time to MNPI Disclosures    
Name   Shannon R. Morris, M.D., Ph.D.
Underlying Securities | shares   137,142
Exercise Price | $ / shares   $ 2.03
Fair Value as of Grant Date | $   $ 202,531
Underlying Security Market Price Change   (1.43)